|
|
SMQ |
|
Vaxjo ID |
479 |
|
Vaccine Adjuvant Name |
SMQ |
|
Adjuvant VO ID |
VO_0005756
|
|
Description |
squalene-in-water emulsion based combination adjuvant with saponin and TLR4 agonist that induces Th1/Th2 balanced response |
|
Stage of Development |
Research |
|
Location Licensed |
United Kingdom |
|
Host Species for Testing |
Mouse |
|
Components |
5 ug QS-21 and 2 ug TLR4 agonist 3D6AP |
|
Preparation |
squalene-in-water emulsion with cholesterol combined with saponin and TLR4 agonist |
|
Function |
Type: combination vaccine adjuvant. Target Receptor: Toll-like receptor 4 (TLR4). Induces Th1/Th2 mixed immune profile. innate immune activation via TLR4 signaling and chemokine induction/enhanced antigen uptake |
| References |
Reinke et al., 2023: Reinke S, Pantazi E, Chappell GR, Sanchez-Martinez A, Guyon R, Fergusson JR, Salman AM, Aktar A, Mukhopadhyay E, Ventura RA, Auderset F, Dubois PM, Collin N, Hill AVS, Bezbradica JS, Milicic A. Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms. Cell reports. Medicine. 2023; 4(11); 101245. [PubMed: 37913775].
|
|
